Thailand public health researchers are confronting a significant reality: lingering SARS-CoV-2 spike proteins in the body may be triggering dormant herpesviruses to reactivate—a phenomenon that could explain the stubborn, multi-system symptoms affecting long COVID patients. New studies from 2026, including research from Japan, China, and Europe, suggest spike proteins don't vanish after acute infection but persist for months, destabilizing immune surveillance and allowing viruses like Epstein-Barr (EBV), cytomegalovirus (CMV), and Human Herpesvirus 6 (HHV-6) to resurface.
For the estimated hundreds of thousands of Thai residents struggling with chronic fatigue, cognitive fog, and unexplained pain months after COVID-19, this research offers both a biological explanation and a pathway toward more targeted diagnostics and treatment.
Why This Matters
• Spike proteins may persist in tissues and blood for up to 12 months post-infection, driving chronic immune dysregulation
• Reactivated herpesviruses (EBV, HHV-6, CMV) produce inflammatory proteins linked to fatigue, depression, and neurological symptoms
• Retinal damage from long COVID is now documented, with nerve fiber loss and microvascular changes detectable on specialized scans—suggesting similar damage may be occurring in the brain
• Standard eye exams often miss these changes, meaning patients need advanced imaging to detect post-COVID retinal dysfunction
The Biological Trigger: Spike Proteins That Outstay Their Welcome
Unlike vaccine-derived spike proteins, which typically clear within 4 weeks, spike proteins from SARS-CoV-2 infection have been detected in blood and tissues for far longer—up to 31 months in documented cases. A subset of long COVID patients showed persistent spike protein presence one year after recovery, a phenomenon not observed in those who fully recuperated.
Why this matters for your immune system:
This extended presence creates chronic immune activation. The spike protein's ability to bind ACE2 receptors across organs—including the lungs, heart, gut, and brain—means it continues triggering localized inflammation and immune exhaustion long after acute viral load clears. In severe COVID-19 cases, lymphocytopenia (low white blood cell count) signals weakened immune response, opening the door for latent herpesviruses to reactivate.
Key finding: A February 2026 systematic review found that EBV, HSV-1, CMV, and HHV-6 were frequently reactivated in severe COVID-19 patients. Reactivations also occurred after vaccination, though mechanisms differed—vaccine-associated cases tended toward shingles and oral herpes, while infection-associated cases showed broader systemic herpesvirus reactivation.
The SITH-1 Connection: Understanding Fatigue and Depression
Japanese scientists in July 2026 identified a protein called SITH-1, produced when dormant herpesviruses reactivate, as a major contributor to the debilitating fatigue and mood disorders in long COVID patients. This reinforces the causal chain: COVID-19 infection → herpesvirus reactivation → SITH-1 expression → neuropsychiatric symptoms.
This aligns with January 2026 research explicitly investigating whether spike proteins directly interact with host immune cell proteins, altering innate immunity and permitting HHV-6 and HHV-7 reactivation. Scientists are now mapping the molecular pathways by which spike-induced immune modulation translates into viral reactivation.
Molecular Mimicry and Autoimmunity
Another hypothesis involves molecular mimicry—the spike protein sharing structural features with both human proteins and herpesvirus proteins. This can mislead the immune system into producing antibodies and T-cells that cross-react with the body's own tissues.
For example, EBV's EBNA1 protein mimics GlialCAM, a central nervous system protein, potentially explaining the neuro-inflammatory component of long COVID. Similarly, spike protein fragments may prime immune responses that fail to contain latent herpesviruses while actively contributing to their reactivation and subsequent inflammatory symptoms.
Eye Damage as a Window into Brain Health
One of the most important findings from 2026 research is the extent of retinal damage in long COVID patients—with direct implications for anyone in Thailand experiencing lingering vision problems after infection.
What the research shows:
A January 2026 longitudinal study from West China Hospital, Sichuan University, using advanced optical coherence tomography (OCT), found significant reductions in:
• Peripheral retinal nerve fiber layer (pRNFL) thickness
• Ganglion cell layer integrity
• Blood vessel density in superficial and deep capillary networks
These changes were evident one month post-infection and persisted for at least one year.
In July 2026, Linköping University researchers reported that 31% to 35% of long COVID patients experienced persistent eye symptoms—pain, light sensitivity, blurred vision, difficulty reading—even when routine exams appeared normal. These patients showed fewer corneal nerve fibers, a weakened blink reflex, and abnormal tear fluid protein patterns consistent with immune dysregulation and nerve injury.
Critical insight: Standard eye exams are insufficient; specialized imaging and tear analysis are required to detect post-COVID eye syndrome.
Northwestern Medicine (February 2025) demonstrated that reduced retinal blood vessel density mirrors microvascular damage in other organs, including the brain. This could explain cognitive fog, memory lapses, and concentration difficulties. The retina serves as a non-invasive biomarker for systemic microvascular and neurological injury.
What Thailand Residents Should Do
For expatriates and long-term residents in Thailand, particularly those managing chronic health conditions or navigating the Thai healthcare system, these findings have practical implications:
Specialized Testing:
• Request optical coherence tomography (OCT) if experiencing persistent vision changes, fatigue, or cognitive symptoms post-COVID
• Ask for tear fluid protein analysis—standard exams often miss damage
• Request blood tests for EBV, CMV, and HHV-6 reactivation to identify underlying inflammation
Where to Get Tested in Thailand:
• Major Bangkok hospitals (Bumrungrad International, Samitivej, Bangkok Hospital) offer OCT imaging; costs typically range from 2,000-4,000 THB
• Thai Ministry of Public Health expanded post-COVID clinics in major provincial hospitals
• Most expat insurance plans cover specialized eye imaging; verify with your provider before testing
Long-Term Monitoring:
• Enroll in post-COVID monitoring programs if symptoms persist beyond 3 months
• Schedule follow-up OCT imaging at 6-month intervals if initial testing shows retinal changes
• Keep detailed records of all specialist visits and test results
Workplace and Insurance:
• Long COVID is increasingly recognized as a disabling condition
• Document all specialist visits and test results for potential insurance claims or workplace accommodations
Diagnostic Challenges and Emerging Tools
The persistent nature of spike protein-driven immune dysregulation and subtle herpesvirus reactivation present diagnostic challenges. Many patients report being dismissed when standard labs return normal. However, researchers are developing diagnostic models integrating:
• Advanced OCT and OCTA imaging for retinal microvascular analysis
• Tear fluid proteomics to detect inflammation and nerve injury markers
• Serial herpesvirus IgG titer monitoring and viral load testing
• Comprehensive immune profiling, including T-cell subset analysis and autoantibody panels
Thailand-based medical institutions, including those affiliated with the Department of Medical Sciences, have been exploring spike protein detection methodologies since December 2025. This underscores domestic capacity for advanced protein analysis that could be adapted for clinical diagnostics.
What Comes Next: Progress and Available Interventions
As of mid-2026, researchers are actively investigating the precise molecular pathways by which SARS-CoV-2 spike proteins trigger herpesvirus reactivation. What is clear is that spike protein plays a central role in the persistent immune dysregulation characteristic of long COVID, and this environment strongly correlates with herpesvirus reactivation.
Ongoing research initiatives:
• Projects launched in early 2026 aim to uncover these mechanisms using systems biology and single-cell sequencing
• Researchers are developing targeted therapies—antiviral agents, immune modulators, and monoclonal antibodies that neutralize circulating spike protein fragments
• Clinical protocols are being developed to improve quality of life for long COVID patients
The positive outlook: Evidence increasingly points toward specific, treatable mechanisms. For a significant subset of patients experiencing persistent symptoms, identifying these pathways enables targeted interventions rather than symptomatic treatment alone.
Thailand's public health infrastructure, along with global research networks, is translating these findings into clinical protocols that can meaningfully improve outcomes for residents navigating life after COVID. The combination of specialized diagnostic tools now available and emerging targeted treatments offers genuine hope for recovery.
